Zimmer Biomet Announces Third Quarter 2021 Financial Results

Go back to Zimmer Biomet Announces Third Quarter 2021 Financial Results

Zimmer Biomet (ZBH) PT Lowered to $175 at Jefferies

November 5, 2021 8:17 AM EDT

Jefferies analyst Raj Denhoy lowered the price target on Zimmer Biomet (NYSE: ZBH) to $175.00 (from $200.00) while maintaining a Buy rating.

The analyst commented, "Key 2Q post call details: 1) Delta/Staffing impacts are expected to persist into 4Q at heightened level, 2) China VBP... More

Zimmer Biomet (ZBH) PT Lowered to $175 at Truist Securities

November 4, 2021 6:09 PM EDT

Truist Securities analyst Kaila Krum lowered the price target on Zimmer Biomet (NYSE: ZBH) to $175.00 (from $188.00) while maintaining a Buy rating.

The analyst commented, "The third quarter was another noisy event for Zimmer Biomet headlined by COVID, staffing, and VBP headwinds that impacted... More

Zimmer Biomet (ZBH) PT Lowered to $175 at Needham & Company

November 4, 2021 1:45 PM EDT

Needham & Company analyst Mike Matson lowered the price target on Zimmer Biomet (NYSE: ZBH) to $175.00 (from $187.00) while maintaining a Strong Buy rating.

The analyst commented, "ZBH's 3Q21 revenue missed while EPS beat consensus. Growth slowed due to procedure disruption and a tougher comp... More

Zimmer Biomet Holdings (ZBH) Tops Q3 EPS by 1c, Lowers FY Guidance

November 4, 2021 6:34 AM EDT

Zimmer Biomet Holdings (NYSE: ZBH) reported Q3 EPS of $1.81, $0.01 better than the analyst estimate of $1.80. Revenue for the quarter came in at $1.92 billion versus the consensus estimate of $1.96 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2021 EPS of $7.32-$7.47, versus the consensus of... More